PXL065

PXL065 is a deuterium-stabilized R-stereoisomer of pioglitazone. It is currently under development by DeuteRx, an American pharmaceutical company, for the treatment of non-alcoholic steatohepatitis (NASH).

Chemistry

PXL065 is a deuterium-stabilized R-stereoisomer of pioglitazone. The deuterium substitution is intended to stabilize the R-stereoisomer and prevent its conversion to the S-stereoisomer, which is associated with the side effects of pioglitazone.

Pharmacology

PXL065 is believed to exert its therapeutic effects through the activation of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that regulates lipid metabolism and glucose homeostasis. By activating PPARγ, PXL065 may reduce hepatic steatosis, inflammation, and fibrosis, the key pathological features of NASH.

Clinical development

PXL065 is currently in Phase 2 clinical trials for the treatment of NASH. The trials are designed to evaluate the safety and efficacy of PXL065 in reducing hepatic fat and inflammation in patients with NASH.

Potential advantages

PXL065 may offer several potential advantages over pioglitazone. First, by stabilizing the R-stereoisomer, PXL065 may reduce the side effects associated with the S-stereoisomer of pioglitazone, such as weight gain and fluid retention. Second, PXL065 may have a more favorable pharmacokinetic profile than pioglitazone, potentially allowing for lower dosing and reduced drug-drug interactions.

See also

• Pioglitazone
• Non-alcoholic steatohepatitis
• Deuterium
• Peroxisome proliferator-activated receptor gamma